Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $108.11

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $108.1111.

Several equities research analysts recently issued reports on the stock. Mizuho cut their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday, July 29th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. B. Riley Financial lowered Lantheus from a “buy” rating to a “neutral” rating in a research note on Monday. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and decreased their target price for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday, August 3rd.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently modified their holdings of the stock. ABS Investment Management LLC bought a new stake in shares of Lantheus during the 2nd quarter worth about $232,974,000. Western Wealth Management LLC acquired a new position in Lantheus in the 1st quarter valued at about $25,000. Osterweis Capital Management Inc. bought a new position in Lantheus in the 2nd quarter valued at about $36,000. Allworth Financial LP bought a new position in Lantheus in the 2nd quarter valued at about $49,000. Finally, Smartleaf Asset Management LLC lifted its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

NASDAQ LNTH opened at $100.26 on Wednesday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The firm’s fifty day moving average price is $104.25 and its two-hundred day moving average price is $89.81. Lantheus has a 1 year low of $49.67 and a 1 year high of $111.86. The firm has a market capitalization of $6.54 billion, a P/E ratio of 24.22 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.57 EPS. As a group, research analysts anticipate that Lantheus will post 4.5 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.